Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Merck Gesellschaft mbH.
ONTARGET - Ongoing telmisartan alone and in combination with ramipril global endpoint trial und TRANSCEND - Telmisartan randomized assessment study in ACE-I intolerant subjects with cardiovascular disease (30 Abbildungen)
Übersicht
Gesamtpräsentation zum Download (rechte Maustaste und "Ziel speichern unter..." klicken)


Zum ersten Bild Abb. 14: ONTARGET - a global trial Abb. 15: ONTARGET - participating countries Abb. 16: ONTARGET will be the largest ARB trial to date Aktuelles Bild - Abb. 17: ONTARGET - patient profile Abb. 18: ONTARGET - study design Abb. 19: ONTARGET - study design Abb. 20: ONTARGET - time line Zum letzten Bild
Abbildung 17: ONTARGET - patient profile
The ONTARGET patient population will be 55 years of age or more. Patients will be at high risk of cardiovascular disease due to a history of coronary artery disease, stroke, peripheral vascular disease or diabetes mellitus type 1 or 2 with end-organ damage (microalbuminuria, abnormal ankle/brachial index [<0.8] or left ventricular hypertrophy). Patients with congestive heart failure will be excluded from the study.
 
ONTARGET - patient profile
Vorheriges Bild Nächstes Bild   


Abbildung 17: ONTARGET - patient profile
The ONTARGET patient population will be 55 years of age or more. Patients will be at high risk of cardiovascular disease due to a history of coronary artery disease, stroke, peripheral vascular disease or diabetes mellitus type 1 or 2 with end-organ damage (microalbuminuria, abnormal ankle/brachial index [<0.8] or left ventricular hypertrophy). Patients with congestive heart failure will be excluded from the study.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung